What is enGene Holdings Probability of Financial Distress (%)?
Probability of Financial Distress (%) measures the probability that a company will go bankrupt in the upcoming year given its current financial position. A higher ratio indicates a larger probability of bankruptcy for the company, while a lower ratio indicates a healthier fundamental. As of today, enGene Holdings's Probability of Financial Distress (%) is 50.00%.
Like the Altman Z-Score, the PFD measures a company's bankruptcy risk. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.
Competitive Comparison of enGene Holdings's Probability of Financial Distress (%)
For the Biotechnology subindustry, enGene Holdings's Probability of Financial Distress (%), along with its competitors' market caps and Probability of Financial Distress (%) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
enGene Holdings's Probability of Financial Distress (%) Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, enGene Holdings's Probability of Financial Distress (%) distribution charts can be found below:
* The bar in red indicates where enGene Holdings's Probability of Financial Distress (%) falls into.
enGene Holdings Probability of Financial Distress (%) Calculation
Probability of Financial Distress (%) (PFD) was developed by John Campbell, Jens Hilscher and Jan Szilagyi in their Search of Distress Risk. It measures the probability that a company will go bankrupt within the next 12 months given its current financial position.
The Probability of Financial Distress (%) was obtained by a logit probability model based on eight explanatory variables. The logit formula to compute the probability of financial distress (LPFD) is given below:
| LPFD | = | -20.12 * NIMTAAVG | + | 1.60 * TLMTA | - | 7.88 * EXRETAVG | + | 1.55 * SIGMA | - | 0.005 * RSIZE | - | 2.27 * CASHMTA | + | 0.070 * MB | - | 0.09 * PRICE | - | 8.87 |
| = | 0.00 |
The Probability of Financial Distress (%) (PFD) was then obtianed by:
| PFD | = | 1 | / | (1 + e^(-LPFD)) | * | 100% |
| = | 50.00% |
The eight explanatory variables are:
1. NIMTAAVG = Net Income to Market Total Assets
*Note that for companies reported quarterly, geometrically declining weighted quarterly Net Income data in latest four quarters are used.
2. TLMTA = Total liabilities to Market Total Assets
3. CASHMTA = Cash to Market Total Assets
For non-financial companies, CASHMTA is measured as:
4. EXRETAVG = Excess Return compared to the S&P 500
EXRETAVG is the weighted excess return compared to the S&P 500 in past 12 month. Geometrically declining weights are imposed on the monthly excess return to reflect lagged information. The weight is halved each quarter.
5. SIGMA = Standard Deviation of Daily Returns
For sigma, we use the annualized standard deviation of a company's returns over the past 92 days (or 63 trading days).
6. RSIZE = Relative Size
| RSIZE | = | log (Market Cap | / | Total Market Cap of S&P 500 companies) |
7. MB = Market to Adjusted Book Equity Ratio
8. PRICE
PRICE is measured as the log of the stock price, capped at log(15).
enGene Holdings (enGene Holdings) Business Description
Traded in Other Exchanges
N/A
Address
7171 Rue Frederick Banting, Saint-Laurent, QC, CAN, H4S 1Z9
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
Executives
| Richard M Glickman |
director |
C/O ASPREVA PHARMACEUTICALS CORPORATION, 1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8 |
| Jason David Hanson |
director, officer: Chief Executive Officer |
8125 NORTH HAYDEN ROAD, SCOTTSDALE AZ 85258-2463 |
| Lumira Capital Investment Management Inc. |
10 percent owner |
141 ADELAIDE STREET WEST, SUITE 770, TORONTO A6 M5H 3L5 |
| Richard Paul Bryce |
officer: Chief Medical Officer |
C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024 |
| Fonds De Solidarite Des Travailleurs Du Quebec |
10 percent owner |
545 CREMAZIE BLVD. EAST, SUITE 200, MONTREAL A8 H2M 2W4 |
| Gerald A Brunk |
director |
C/O MDS CAPITAL, 245 FIRST ST., STE 1800, CAMBRIDGE MA 02142 |
| Jasper Bos |
director |
BOUNDARY HALL, PO BOX 1093, CRICKET SQUARE, GRAND CAYMAN E9 KY1-1102 |
| Grassin Alexandre Jean-rene Erwan |
officer: Int. Chief Financial Officer |
7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9 |
| Anthony Tzeyew Cheung |
officer: Chief Technology Officer |
7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9 |
| Alexander Julian Nichols |
officer: Pres. & Chief Operating Ofc. |
7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9 |
| James Crowley Sullivan |
officer: Chief Scientific Officer |
7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9 |
| Forbion Growth Sponsor Feac I B.v. |
10 percent owner |
GOOIMEER 2 35,, NAARDEN P7 1411DC |
| Forbion Growth Opportunities Fund I Cooperatief U.a. |
10 percent owner |
GOOIMEER 235, 1411 DC, NAARDEN P7 00000 |
| Forbion Growth Management B.v. |
10 percent owner |
C/O FORBION EUROPEAN ACQUISITION CORP., 4001 KENNETT PIKE, SUITE 302, WILMINGTON DE 19807 |
enGene Holdings (enGene Holdings) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ENGN has been successfully added to your